生物活性 | |||
---|---|---|---|
描述 | Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1). I3C inhibits the proliferation of THP-1 cells in a dose- and time-dependent manner with minimal toxicity over normal monocytes. I3C could exert its antileukemic effects through AhR activation which is associated with programed cell death and G1 cell cycle arrest in a dose- and time-dependent manner[3]. Treatment with I3C led to repressed colonic inflammation and prevention of microbial dysbiosis caused by colitis, increasing a subset of gram-positive bacteria known to produce butyrate. I3C attenuates colitis primarily through induction of IL-22, which leads to modulation of gut microbiota that promote antiinflammatory butyrate[4]. I3C prevented EtOH (ethanol) -induced liver injury via attenuating the damaging effect of ethanol on the gut-liver-adipose tissue axis[5]. I3C may induce apoptosis in human osteosarcoma MG-63 and U2OS cells via the activation of apoptotic signaling pathways by FOXO3[6]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00910884 | - | Not yet recruiting | February 2020 | United States, Washington ... 展开 >> Brabant Research, Incorporated Not yet recruiting Spokane Valley, Washington, United States, 99216 Contact: Richard E. Lasker, PhD 509-340-9902 rel@brabantresearch.com 收起 << | |
NCT02483624 | SLE | Phase 1 | Terminated | - | - |
NCT02525159 | Breast Cancer | Phase 3 | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
6.79mL 1.36mL 0.68mL |
33.97mL 6.79mL 3.40mL |
67.95mL 13.59mL 6.79mL |
参考文献 |
---|